Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics

Multiple lines of evidence suggest a potential role for the kappa dynorphin system in schizophrenia and its therapeutics. Kappa stimulation acutely and chronically modulates dopamine in opposite ways, where acutely it decreases dopamine transmission and chronically it increases it and it can induce...

Descripción completa

Detalles Bibliográficos
Autor principal: Abi-Dargham, Anissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442669/
https://www.ncbi.nlm.nih.gov/pubmed/34532594
http://dx.doi.org/10.20900/jpbs.20210015
_version_ 1783753049227919360
author Abi-Dargham, Anissa
author_facet Abi-Dargham, Anissa
author_sort Abi-Dargham, Anissa
collection PubMed
description Multiple lines of evidence suggest a potential role for the kappa dynorphin system in schizophrenia and its therapeutics. Kappa stimulation acutely and chronically modulates dopamine in opposite ways, where acutely it decreases dopamine transmission and chronically it increases it and it can induce D2 sensitization. In addition, pharmacological evidence from studies using agonist and antagonists at KOR have indicated a therapeutic potential of KOR antagonists for psychosis. We present here a brief overview of the evidence supporting this viewpoint.
format Online
Article
Text
id pubmed-8442669
institution National Center for Biotechnology Information
language English
publishDate 2021
record_format MEDLINE/PubMed
spelling pubmed-84426692021-09-15 Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics Abi-Dargham, Anissa J Psychiatr Brain Sci Article Multiple lines of evidence suggest a potential role for the kappa dynorphin system in schizophrenia and its therapeutics. Kappa stimulation acutely and chronically modulates dopamine in opposite ways, where acutely it decreases dopamine transmission and chronically it increases it and it can induce D2 sensitization. In addition, pharmacological evidence from studies using agonist and antagonists at KOR have indicated a therapeutic potential of KOR antagonists for psychosis. We present here a brief overview of the evidence supporting this viewpoint. 2021-08-24 2021 /pmc/articles/PMC8442669/ /pubmed/34532594 http://dx.doi.org/10.20900/jpbs.20210015 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms and conditions of Creative Commons Attribution 4.0 International License. http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Article
Abi-Dargham, Anissa
Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics
title Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics
title_full Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics
title_fullStr Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics
title_full_unstemmed Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics
title_short Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics
title_sort relevance of the kappa dynorphin system to schizophrenia and its therapeutics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442669/
https://www.ncbi.nlm.nih.gov/pubmed/34532594
http://dx.doi.org/10.20900/jpbs.20210015
work_keys_str_mv AT abidarghamanissa relevanceofthekappadynorphinsystemtoschizophreniaanditstherapeutics

Ejemplares similares